NGeneBio participated in the World Conference on Lung Cancer (WCLC 2023), held in Singapore from September 9 to 12, 2023.

During this conference, NGeneBio focused on introducing "ctDNAaccuPanel™ Lung," a blood-based precision diagnostic technology for lung cancer monitoring, which is set to be launched in December. This panel aims to overcome the limitations of tissue biopsy and offers early detection of resistance to anticancer drugs, providing solutions for cancer diagnosis and treatment. NGeneBio also presented various precision cancer diagnostic products based on NGS technology.

The high level of interest from the medical community regarding the upcoming liquid biopsy product release at the end of the year was evident. Healthcare professionals from various countries, including Morocco and the Philippines, visited the booth, showing a strong interest in liquid biopsy. NGeneBio plans to capitalize on this positive response from the medical community by actively showcasing its precision diagnostic products in the global market and strengthening product exports to overseas medical institutions.

For more detailed information about WCLC 2023, please visit Home - WCLC 2023 (iaslc.org).